Is MRI/TRUS fusion-guided prostate biopsy cost-efficient for all patients?

Slowly but perhaps inexorably we seem to be seeing increasing scientific and clinical justification for the argument that all men thought to be at risk for a diagnosis of prostate cancer should be given an MRI scan prior to any form of prostate biopsy. … READ MORE …

What patients are willing to pay for an MRI-guided biopsy (maybe)

A recent report in Urology Practice makes what we see as a somewhat odd statement about what patients may be willing to pay for an MRI/TRUS fusion-guided biopsy as opposed to a TRUS-guided prostate biopsy. … READ MORE …

Might we see generic abiraterone acetate this year?

On Wednesday the U.S. Patent Trial and Appeal Board invalidated the last remaining patent on abiraterone acetate (Zytiga), making it possible that generic forms of abiraterone acetate would be available in 2018 (at least in the US). … READ MORE …

The cost and the effectiveness of genomic testing for prostate cancer risk

As regular readers will be well aware, there are now several different tests available that can be used to assess risk for low- and very low-risk forms of prostate cancer at time of diagnosis (as opposed to clinically significant forms that need early treatment). … READ MORE …

The price — and the politics — of drug therapy for advanced prostate cancer

According to a story on the MarketWatch web site yesterday, two not-for-profit organizations have been seeking hearings on revocation of patents held by Medivation on the drug enzalutamide (Xtandi). … READ MORE …

A highly qualified “thank you” to Drs. Welch and Albertsen — maybe?

The prostate cancer patient community should be aware of an “op-ed” in today’s New York Times by Drs. Gilbert Welch and Peter Albertsen arguing that Medicare should continue to let individual physicians make their own decisions about the use of the PSA test for risk of prostate cancer. … READ MORE …

Something you can do NOW about the cost of care and “financial toxicities”

In an article in the October 25 issue of The ASCO Post, Dr. Jonas de Souza of the University of Chicago has introduced a new initiative to help all cancer patients and their doctors address the increasing problems associated with the costs of cancer care. … READ MORE …